SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias sharp drop is part of a broader semiconductor selloff as traders reassess AI infrastructure spending amid post-election concerns that data-center opposition and regulation could slow new projects. The community is split between fears that slower buildout could undermine chip demand and views that the concerns are overblown and the selloff is a buying opportunity.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs quarterly results and sharply raised 2026 revenue outlook, supported by a Sanofi vaccine-trial milestone, are driving discussion. Although many traders view the earnings beat and licensing strategy positively, others are frustrated by the share-price decline and question the reliance on milestone income, the delayed profitability target, and the lack of new partnerships or pipeline data.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs target decision on deramiocel for Duchenne muscular dystrophy, with discussion focused on a letter from 28 HOPE-3 investigators urging approval and challenging the FDAs interpretation of the trial data. Many traders are bullish on the drugs upper-limb results and speculate about a short squeeze, while others emphasize that approval is uncertain and a rejection or CRL remains possible.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOIs shares sold off sharply despite a quarterly earnings beat, as its next-quarter revenue outlook came in below expectations and management said U.S. capacity expansion would take longer amid power and construction delays. Bulls point to the hyperscaler agreement and continued demand for data-center optics, while bears focus on execution, margins, and uncertainty around AI infrastructure spending.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is drawing attention after a steep semiconductor selloff, with traders pointing to fears that political opposition or tighter rules could slow data-center construction and weaken AI chip spending. The community is split between warnings that AI-capex and financing concerns signal a deeper downturn and views that the drop is an overreaction because demand remains strong.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Roots quarterly results sparked a sharp selloff, with traders focusing on declining premiums and flat-to-lower policies in force despite positive earnings and improved underwriting. Bulls point to profitability and share buybacks as support, while bears argue stalled growth weakens the investment case.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins strong third-quarter results, above-consensus outlook and expanded buyback sparked a sharp rally, with traders crediting improved performance from its advertising model and renewed confidence in growth. Many celebrated the rebound and resilience during a broader market selloff, while others warned that the rapid run-up could invite profit-taking and questioned whether the gains would hold.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles selloff is centered on concerns that political and local opposition could slow AI data-center expansion, with a New Mexico power-permit delay adding to the uncertainty. Traders also debate whether Oracles debt-funded buildout and AI commitments can generate cash quickly enough; bearish calls about financing risks compete with dip-buying and confidence that demand for AI infrastructure will persist.

Airbnb, Inc. engages in the management and operation of an online marketplace. Its marketplace model connects hosts and guests online or through mobile devices to book spaces. The company was founded by Brian Chesky, Nathan Blecharczyk and Joseph Gebbia in 2007 and is headquartered in San Francisco, CA.

Airbnb Inc - Ordinary Shares - Class A

Airbnb Inc

Airbnbs Q3 earnings beat and stronger outlook, alongside a new buyback authorization, are driving attention and a strong post-earnings reaction. Bulls see accelerating bookings and growth, while skeptics question whether the rally can hold amid broader market weakness and concerns about cash-flow margins.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Strong quarterly results, higher revenue guidance, and a faster path to major Recorlev sales growth are driving Xeriss sharp rally. Traders are broadly celebratory, while some speculate about a takeover and others caution that the deal chatter is unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Feed

News

Sentiment

Fundamentals

Info

About AMYT